 |
4 Diseases |  |
0 Trials |
|
0 Trials |  |
8 News |  |
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen, Takeda, U3-1565 / Daiichi Sankyo
Clinical, P1 data, Journal: Phase I study of the anti-heparin-binding epidermal growth factor-like growth factor antibody U3-1565 with cetuximab in patients with cetuximab- or panitumumab-resistant metastatic colorectal cancer. (Pubmed Central) - Mar 4, 2021
The efficacy of this combination therapy after progression on Cetu/Pani was negligible. Trial Registration: UMIN000013006.
- || U3-1565 / Daiichi Sankyo
Clinical, P1 data, Journal: First-in-human study of the anti-HB-EGF antibody U3-1565 in subjects with advanced solid tumors. (Pubmed Central) - Jan 23, 2020
Subjects with high VEGF-A baseline levels remained on treatment longer (3/6 entered study extension phase versus 1/30), and were more likely to show disease control (3/6 versus 4/30). In conclusion, U3-1565 demonstrates both proof of mechanism and clinical activity across different tumor types.
- U3-1565 / Daiichi Sankyo
Trial primary completion date, Metastases: Study to Assess the Safety and Tolerability of U3-1565 in Subjects With Advanced Solid Malignant Tumors (clinicaltrials.gov) - May 15, 2014
P1, N=36, Completed, Sponsor: Daiichi Sankyo Inc.
In conclusion, U3-1565 demonstrates both proof of mechanism and clinical activity across different tumor types. Trial primary completion date: Jun 2013 --> Jan 2013
- U3-1565 / Daiichi Sankyo
Trial completion date, Metastases: Study to Assess the Safety and Tolerability of U3-1565 in Subjects With Advanced Solid Malignant Tumors (clinicaltrials.gov) - May 15, 2014
P1, N=36, Completed, Sponsor: Daiichi Sankyo Inc.
Trial primary completion date: Jun 2013 --> Jan 2013 Trial completion date: Dec 2014 --> Jan 2013
- U3-1565 / Daiichi Sankyo
Enrollment change, Metastases: Study to Assess the Safety and Tolerability of U3-1565 in Subjects With Advanced Solid Malignant Tumors (clinicaltrials.gov) - May 15, 2014
P1, N=36, Completed, Sponsor: Daiichi Sankyo Inc.
Trial completion date: Dec 2014 --> Jan 2013 N=66 --> 36
- | U3-1565 / Daiichi Sankyo
Trial completion, Metastases: Study to Assess the Safety and Tolerability of U3-1565 in Subjects With Advanced Solid Malignant Tumors (clinicaltrials.gov) - May 15, 2014
P1, N=36, Completed, Sponsor: Daiichi Sankyo Inc.
N=66 --> 36 Active, not recruiting --> Completed
- || U3-1565 / Daiichi Sankyo
Enrollment closed, Metastases: Study to Assess the Safety and Tolerability of U3-1565 in Subjects With Advanced Solid Malignant Tumors (clinicaltrials.gov) - Jun 10, 2013
P1, N=66, Active, not recruiting, Sponsor: Daiichi Sankyo Inc.
Active, not recruiting --> Completed Recruiting --> Active, not recruiting